Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
Aaron T. Gerds, Srđan Verstovšek, Alessandro M. Vannucchi, et al.
The Lancet Haematology (2023) Vol. 10, Iss. 9, pp. e735-e746
Closed Access | Times Cited: 23

Showing 23 citing articles:

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
Claire Harrison, Ruben A. Mesa, Moshe Talpaz, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 10, pp. e729-e740
Closed Access | Times Cited: 6
Momelotinib: First Approval
Susan J. Keam
Drugs (2023) Vol. 83, Iss. 18, pp. 1709-1715
Closed Access | Times Cited: 13
A novel application of XPO1 inhibition for the treatment of myelofibrosis
Megan Metzger, Zachary M. Avigan, Pankit Vachhani, et al.
Deleted Journal (2024) Vol. 1, Iss. 2, pp. 100010-100010
Open Access | Times Cited: 4
Clearance of Driver Mutations after Transplantation for Myelofibrosis
Nico Gagelmann, Marie Quarder, Anita Badbaran, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 2, pp. 150-160
Closed Access
SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms
Joseph Cannova, Shiv Shah, Anand Patel
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2025)
Closed Access
Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review
Nico Gagelmann, Nicolaus Kröger
American Journal of Hematology (2025)
Open Access
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis
Andrea Duminuco, Helen T. Chifotides, Sebastiano Giallongo, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 154-154
Open Access | Times Cited: 12
Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation
Nico Gagelmann, Claudia Schuh, Robert Zeiser, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 10, pp. 1011.e1-1011.e13
Open Access | Times Cited: 2
Clinical and Immune Effects of Peri‐Transplantation JAK Inhibition for Myelofibrosis
Kristin Rathje, Nico Gagelmann, Anita Badbaran, et al.
American Journal of Hematology (2024)
Open Access | Times Cited: 2
Momelotinib for the treatment of myelofibrosis
Prithviraj Bose
Blood (2024) Vol. 144, Iss. 7, pp. 708-713
Closed Access | Times Cited: 1
MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients
Stefanie Jilg, Juliana Schwaab, Katja Sockel, et al.
Annals of Hematology (2024) Vol. 103, Iss. 10, pp. 4065-4077
Closed Access | Times Cited: 1
Navigating ‘grey areas’ and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT
Nicola Polverelli, Juan Carlos Hernández‐Boluda, Nico Gagelmann, et al.
Bone Marrow Transplantation (2024)
Closed Access | Times Cited: 1
Momelotinib in myelofibrosis and beyond: a comprehensive review of therapeutic insights in hematologic malignancies
Parisa Alsadat Dadkhah, Mohammad Amin Karimi, Mohammad Sadra Gholami Chahkand, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access
Myelofibrose: Ein Tyrosinkinase-Inhibitor erweitert die therapeutischen Möglichkeiten
Sonja Heibl
Kompass Onkologie (2024) Vol. 11, Iss. 3, pp. 128-129
Closed Access
SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis
Michael J. Hochman, Colin A. Vale, Anthony M. Hunter
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology
Edoardo Peroni, Elisabetta Calistri, Rosario Amato, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
Yi Zhang, Hu Zhou, Shanshan Suo, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access
Controlling HLH: dealing JAKs from the pack
Adi Zoref‐Lorenz
Blood (2024) Vol. 143, Iss. 23, pp. 2342-2344
Open Access
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature
Anthony M. Hunter, Prithviraj Bose
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 10, pp. 1391-1404
Closed Access
Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis
James T. England, Taylor Nye, Verna Cheung, et al.
Bone Marrow Transplantation (2024)
Closed Access
Novel approaches in myelofibrosis
Steffen Koschmieder
HemaSphere (2024) Vol. 8, Iss. 12
Open Access
Maintaining MOMENTUM in myelofibrosis
Marina Kremyanskaya, Bridget K. Marcellino
The Lancet Haematology (2023) Vol. 10, Iss. 9, pp. e697-e699
Closed Access
Page 1

Scroll to top